JPMorgan Boosts Edgewise Therapeutics Target to $45: Bullish on 2026 Catalysts and EDG-7500 Momentum

JPMorgan boosts Edgewise Therapeutics price target to $45 from $34, maintains Overweight rating. Bullish on EDG-7500 catalysts and strong 2026 setup.